Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of March 2023, specifically dated March 6, 2023. The report serves to incorporate by reference a press release regarding a clinical milestone in the Company's oncology pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development update and does not contain financial statements or performance data.
Material Changes
The material change reported is the initiation of a clinical trial. On March 6, 2023, Compugen Ltd. announced that it has dosed the first patient in a proof-of-concept study evaluating a triple combination therapy.
Guidance, Outlook, and Management Commentary
- Clinical Milestone: The Company has dosed the first patient in a study combining COM701, COM902, and Pembrolizumab.
- Indication: The study targets patients with Microsatellite Stable (MSS) Colorectal Cancer (CRC).
- Study Type: This is designated as a proof-of-concept study.
- Outlook: The filing does not provide specific financial guidance or future revenue projections.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study design and enrollment criteria.
- Confirm the regulatory status and approval of the triple combination protocol.
- Review the Company's most recent Form 20-F for current cash runway and burn rate, as this 6-K contains no financial data.
- Monitor subsequent filings for patient enrollment updates and preliminary safety data from the trial.